Canada markets closed

Glaukos Corp (6GJ.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
93.50+2.50 (+2.75%)
At close: 09:00PM CEST
Full screen
Previous Close91.00
Open91.50
Bid93.00 x 0
Ask95.50 x 0
Day's Range91.50 - 93.50
52 Week Range40.80 - 93.50
Volume0
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • Business Wire

    Glaukos Announces the Release of its 2023 Sustainability Report

    ALISO VIEJO, Calif., April 16, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company’s website here.

  • Business Wire

    Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

    ALISO VIEJO, Calif., April 10, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 1, 2024.

  • Business Wire

    Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

    ALISO VIEJO, Calif., April 03, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for iDose® TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction